Close Menu

NEW YORK ─ With data indicating its Nanotrap technology could help boost the sensitivity of molecular assays for SARS-CoV-S, Ceres Nanosciences is looking to move into testing for the virus.

The company is currently working with a number of labs to incorporate its Nanotrap reagents into their SARS-CoV-2 testing and is in discussion with several in vitro diagnostic vendors about integrating the Nanotrap technology as part of their molecular testing systems, said Robbie Barbero, Ceres' chief business officer.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.